Published in the Journal of Nanobiotechnology, the iPSC-derived therapy delivers BDNF mRNA to injured spinal tissue, improving motor recovery in preclinical studies.
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
Cellular Intelligence will use its AI platform to speed the clinical development and scalable manufacturing of a Phase 1/2 stem cell-derived Parkinson’s therapy acquired from Novo Nordisk, which also took an equity stake in the company.
The funding will support Latus Bio’s lead gene therapy programs in Huntington’s and CLN2 disease while advancing its low-dose AAV delivery platform designed to make gene therapies safer, more scalable, and accessible to broader patient populations.
The recommendation is backed by Phase III data showing that Novartis’ one-time gene therapy improved motor function in people aged two and older with SMA and could lessen reliance on ongoing chronic treatment.
Orthocell has gained approval for its Remplir nerve repair device across U.S. Department of Defence and Veterans Affairs hospital networks, expanding access to more than 220 military and veteran care facilities as it uses its distributor network to drive adoption in trauma-focused surgical settings.
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed an automated manufacturing platform to bring that down, it's currently being used by many companies, including Aspen Neuroscience for its iPSC-derived Parkinson's Phase 3. We sat down with co-founders Ali and…
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
Exo-Top and BioXtek have signed a non-binding letter of intent to explore a partnership focused on GMP manufacturing, clinical supply, and potential commercialization of bone marrow-derived mesenchymal stem cell exosomes.
Longeveron has received a Chinese patent covering potency assay methods used to assess human mesenchymal stem cells from multiple tissue sources and induced pluripotent stem cells, extending the company’s patent rights in China through 2041.
The company has emerged from stealth mode with a new $21 million Series A tranche (bringing total funding to $42 million), appointed Ron Cohen, M.D. as CEO, and reported early Phase 1b/2a Parkinson’s neuron replacement therapy data showing motor improvements and neuroimaging evidence of restored…
This is part of J&J's $55B investment in US manufacturing over the next few years.
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s disease.
ENCell's umbilical cord-derived mesenchymal stem cell therapy candidate EN001 received FDA orphan drug designation for Duchenne muscular dystrophy, marking its second designation after Charcot-Marie-Tooth disease and positioning it as a potential platform therapy for rare neuromuscular diseases.
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a Parkinson’s mouse model.
Stemchymal's CDMO has been selected, while the company seeks conditional approval in both Japan and Taiwan following Phase II results.
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.
South China Morning Post says it spoke with the iPSC research team, who relayed that the brain stem cell implant is showing promise in Parkinson's.
The latest funding round will support US expansion, new stem cell-derived disease models, and increased manufacturing at its Edinburgh site.
Japan’s SAKIGAKE designation may help accelerate development and review of the embryonic stem cell-derived therapy.
The Phase II trial showed significant motor function improvements and safety for an allogeneic stem cell therapy in Parkinson’s disease.
A pioneering UC Irvine study will assess the safety and potential benefits of embryo-derived neural stem cell therapy for Huntington’s disease.
Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal of Medicine, proposing a new pathway. Here are the details.
Nature Cell’s new facility will focus on stem cell therapeutics, research, and manufacturing, supported by the Maryland Stem Cell Research Fund.
The new funding round will help advance their iPSC-derived dopaminergic neuronal precursor cell trials, manufacturing, and continued development of other iPSC therapies.